| Autor: |
Karigyo CJT; Engineering Center for Circulatory Assistance, Instituto Dante Pazzanese de Cardiologia, São Paulo, São Paulo, Brazil.; Postgraduate Program in Medicine/Technology and Intervention in Cardiology, Universidade de São Paulo, São Paulo, São Paulo, Brazil., Pessoa BMS; Faculdade de Medicina, Universidade Federal do Amazonas, Manaus, Amazonas, Brazil., Nicacio SP; Faculdade de Medicina, Universidade Estadual de Londrina, Londrina, Paraná, Brazil., Terwilliger E; Mayo Clinic College of Medicine and Science, Rochester, Minnesota, United States of America., Costa P; Division of Hematology and Oncology, Yale University Yale Cancer Center, New Haven, Connecticut, United States of America., Santos PRD; Division of Cardiothoracic Surgery, Mayo Clinic Arizona, Phoenix, Arizona, United States of America., Ernani V; Division of Oncology, Mayo Clinic Arizona, Phoenix, Arizona, United States of America., Seetharam M; Division of Oncology, Mayo Clinic Arizona, Phoenix, Arizona, United States of America., Murakami AN; Division of Cardiac Surgery, Universidade Estadual de Londrina, Londrina, Paraná, Brazil., Batalini F; Mayo Clinic Arizona Division of Oncology Phoenix Arizona United States of America Division of Oncology, Mayo Clinic Arizona, Phoenix, Arizona, United States of America. |
| Abstrakt: |
Cardiac tumors are rare and encompass a variety of presentations. Clinica symptoms are usually nonspecific, but they can present as obstructive, embolic, or constitutional symptoms. Treatment options and prognosis vary highly depending on the subtype, tumor size, and location. Surgical resection is usually the first-line therapy, except for cardiac lymphomas, and provides favorable long-term prognosis in most benign tumors. Cardiac sarcomas, however, are usually diagnosed in advanced stages, and the treatment relies on a multimodal approach with chemotherapy and radiotherapy. Metastatic cardiac tumors are usually related to advanced disease and carry an overall poor prognosis. |
